CIP2A and chronic obstructive pulmonary disease: Recent findings in HBE cells from COPD patients treated with Erlotinib, resulted in decreased CIP2A expression and subsequent increased PP2A activation, suggesting it may also be applicable in the treatment of COPD [28, 94, 104–106].